Caio Leal Carvalho, Ivana Nascimento Garcia de Santana, Paula Silva Rubio, Tassia Cruz Poit, Joelly Taynara Lapinski Levermann, Cristiane Ferreira Rallo de Almeida, Mário César Miranda Almeida
{"title":"阿达木单抗治疗难治性毛疹糠疹1例","authors":"Caio Leal Carvalho, Ivana Nascimento Garcia de Santana, Paula Silva Rubio, Tassia Cruz Poit, Joelly Taynara Lapinski Levermann, Cristiane Ferreira Rallo de Almeida, Mário César Miranda Almeida","doi":"10.15406/jdc.2023.07.00236","DOIUrl":null,"url":null,"abstract":"Pityriasis Rubra Pilaris (PRP) is a rare inflammatory dermatosis, clinically presenting as a keratinization disorder, with follicular and palmoplantar hyperkeratosis, in addition to orange-red scaly plaques, accompanied by characteristic islands of healthy skin. Sometimes, conventional treatment proves to be ineffective, and this work aims to present a case of a patient with failed first and second lines treatment options, responding well to adalimumab. Despite of all options available, more qualified and specific studies are needed to establish a standardized treatment based on evidence of a high scientific level, thus raising the degree of efficacy and therapeutic safety in PRP.","PeriodicalId":23420,"journal":{"name":"Ukrainian Journal of Dermatology, Venerology, Cosmetology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Refractory Pityriasis rubra pilaris treated with Adalimumab: a case report\",\"authors\":\"Caio Leal Carvalho, Ivana Nascimento Garcia de Santana, Paula Silva Rubio, Tassia Cruz Poit, Joelly Taynara Lapinski Levermann, Cristiane Ferreira Rallo de Almeida, Mário César Miranda Almeida\",\"doi\":\"10.15406/jdc.2023.07.00236\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pityriasis Rubra Pilaris (PRP) is a rare inflammatory dermatosis, clinically presenting as a keratinization disorder, with follicular and palmoplantar hyperkeratosis, in addition to orange-red scaly plaques, accompanied by characteristic islands of healthy skin. Sometimes, conventional treatment proves to be ineffective, and this work aims to present a case of a patient with failed first and second lines treatment options, responding well to adalimumab. Despite of all options available, more qualified and specific studies are needed to establish a standardized treatment based on evidence of a high scientific level, thus raising the degree of efficacy and therapeutic safety in PRP.\",\"PeriodicalId\":23420,\"journal\":{\"name\":\"Ukrainian Journal of Dermatology, Venerology, Cosmetology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ukrainian Journal of Dermatology, Venerology, Cosmetology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/jdc.2023.07.00236\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ukrainian Journal of Dermatology, Venerology, Cosmetology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/jdc.2023.07.00236","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Refractory Pityriasis rubra pilaris treated with Adalimumab: a case report
Pityriasis Rubra Pilaris (PRP) is a rare inflammatory dermatosis, clinically presenting as a keratinization disorder, with follicular and palmoplantar hyperkeratosis, in addition to orange-red scaly plaques, accompanied by characteristic islands of healthy skin. Sometimes, conventional treatment proves to be ineffective, and this work aims to present a case of a patient with failed first and second lines treatment options, responding well to adalimumab. Despite of all options available, more qualified and specific studies are needed to establish a standardized treatment based on evidence of a high scientific level, thus raising the degree of efficacy and therapeutic safety in PRP.